Axsome Therapeutics Inc — Cash Flow (NASDAQ:AXSM) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -78.46 M-108.23 M-116.51 M145.08 M128.41 M93.41 M 93.41 M Cash from investing activities -45.89 K-307.55 K-53.7 M582 K270 K480 K 480 K Cash from financing activities 42.41 M11.13 M284.58 M331.01 M57.84 M101.47 M 101.47 M Free cash flow -78.5 M-108.53 M-117.21 M144.5 M128.14 M92.92 M 92.92 M

Nouvelles

Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

UBS relève l’objectif de cours d’Axsome Therapeutics suite à l’expansion de la force de vente

UBS raises Axsome Therapeutics stock price target on sales force expansion

Wolfe Research initie la couverture d’Axsome avec une recommandation surperformance

Wolfe Research initiates Axsome stock with outperform rating

RBC Capital relève l’objectif de cours d’Axsome Therapeutics

RBC Capital raises Axsome Therapeutics price target on earnings

Axsome traite le premier patient dans un essai sur la dépression avec le solriamfetol

Axsome doses first patient in depression trial with solriamfetol

Guggenheim relève l’objectif de cours d’Axsome à 220$ sur de solides ventes